Navigation Links
Sangamo BioSciences Reports Third Quarter 2008 Financial Results
Date:10/29/2008

nd administrative expenses were $2.6 million for the third quarter of 2008, compared to $1.7 million for the same period in 2007. The increase in general and administrative expenses was primarily due to increased personnel costs, including non-cash stock-based compensation which totaled $709,000 in the third quarter of 2008 compared to $202,000 in the same period in 2007.

Total operating expenses for the third quarter of 2008 were $10.1 million, compared to $7.6 million for the same period in 2007.

Net interest and other income was $42,000 for the third quarter of 2008, compared to $1.1 million for the same period in 2007. The decrease is due to lower average investment balances and lower interest rates as well as a foreign currency translation loss during the quarter.

Nine Month Results

For the nine months ended September 30, 2008, the consolidated net loss was $21.7 million, or $0.53 per share, compared to a net loss of $14.8 million, or $0.41 per share, for the nine-month period ended September 30, 2007. Revenues were $9.4 million for the first nine months of 2008, compared to $6.3 million in the same period in 2007. Total operating expenses were $32.5 million for the first nine months of 2008 and $23.5 million for the same period of 2007. The increase in operating expenses for 2008 was primarily associated with Sangamo's clinical development programs in diabetic neuropathy and pre-IND programs to develop ZFP Therapeutics for the treatment of HIV/AIDS and glioblastoma, as well as increased research and development personnel costs and lab supply expenses.

Recent Highlights

* Initiation of a Phase 2 clinical trial (SB-509-801) to evaluate SB-509

in subjects with Amyotrophic Lateral Sclerosis (ALS). ALS is a

progressive, degenerative motor-neuron disease for which there are

limited treatment options and no cure. The Phase 2 trial is a

randomized repeat-dosing, open-label, multi-cen
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
2. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
3. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
4. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
5. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
6. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
7. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
8. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
9. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
10. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
11. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Based ... the overall surgical imaging market is dominated by ... the surgical imaging market. These players include GE ... Ziehm Imaging (Germany). , Full Report Copy ... of GE Healthcare can be attributed to its ...
(Date:12/17/2014)... Once more, EMAAR has selected BioShaft ... water treatment plant to phase one of BayLaSun, a ... years ago Bioshaft successfully supplied and operated a packaged ... towers with an occupancy of 900 residences. The ... per day and was signed on September 16th, 2014, ...
(Date:12/17/2014)... December 17, 2014 Audacity, a leading ... and member of the Huntsworth Health Group, is proud ... executive team. In her role, Gonzales will serve as ... are incredibly honored to welcome a talent of Jamie’s ... CEO, Gaëtan Fraikin. “She is a proven healthcare innovation ...
(Date:12/17/2014)... Calif. , Dec. 17, 2014 ... a Phase 2 study evaluating the investigational oral ... of patients with severe, chronic itch who are ... of care, including topical steroids and antihistamines. ... change in Visual Analog Scale (VAS) itch score ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... NGSX ), a biopharmaceutical company focused on developing ... results for its fourth quarter and year-end 2007 on ... conference call to review the results will begin at ... and will be hosted by Anthony DiTonno,President and Chief ...
... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), a biotechnology Company ... targeting the chronic inflammation,underlying cardiovascular and neurological disease, ... and Special Meeting of Shareholders,being held at the ... at 4:30 p.m. ET., To participate via ...
... Md., March 18 Martek Biosciences,(Nasdaq: MATK ) ... with,life,sDHA(TM), its patented, vegetarian form of DHA omega-3 for ... bread with vegetarian DHA,Oroweat 9 Grain Bread with life,sDHA ... in the Pacific Northwest, California, Arizona,and Nevada., "This ...
Cached Biology Technology:NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results 2NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results 3Vasogen to Webcast its Annual Meeting 2Vasogen to Webcast its Annual Meeting 3Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 2Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 3
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
(Date:11/15/2014)... , Nov. 13, 2014  While we may still ... Doctor McCoy used in "Star Trek" to gain instant access ... designed to work with smartphones and tablets for monitoring and ... the healthcare world. This may seem a tad Orwellian to ... to adopt some of these technological opportunities into their healthcare ...
(Date:11/11/2014)... Inc., a Chicago -based digital forensics ... of Yaniv Schiff from Senior Computer Forensics ... role as Director, he will lead company efforts to ... provide leadership within the company,s digital forensics practice area.  ... Schiff joined Forensicon in 2006 and has ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... An international team of researchers, including Monash University ... support of one of the key tenets of Darwin,s ... Lithgow said the breakthrough, funded by the Australian Research ... PNAS , provides a blueprint for a general understanding ...
... the plasma membrane keeps epithelial cells in shape and maintains ... et al. The study will appear in the September 21, ... (online September 14). Spectrin, F-actin, and associated proteins form ... red blood cells. A similar network underlies the membranes of ...
... Shinya Yamanaka, MD, PhD, of the Gladstone Institute of ... Albert Lasker Basic Medical Research Award for his discovery of ... stem cells. Yamanaka, who is the L.K.Whittier Investigator in Stem ... is one of the youngest recipients of the award, which ...
Cached Biology News:Evolution still scientifically stable 2Gladstone's Shinya Yamanaka wins Lasker Award 2
... The Genome-pULSe Kit delivers a novel procedure ... (non-enzymatic) labeling of whole genome DNA from ... to provide a quick and highly reproducible ... Genome-pULSe consists of a REPLI-g Mini Kit ...
... Introduction of a protein into cells ... cell signaling pathways, apoptotic pathways, and transcription ... for studying the effects of a specific ... transfect the protein directly into the cell. ...
... is an automated instrument with a thin ... real-time using light or fluorescence microscopy. Biaxial ... and fibroblast cells can be simulated by ... and Y axis of our strain chamber. ...
... entered the next frontier of cell-based High ... Cellomics, Inc. The drug discovery process will ... automated solutions systems and Cellomics‘ HCS technology, ... sub-cellular level. The integration of these systems ...
Biology Products: